aDepartment of Pathology, Clinical Microbiology, Montefiore Medical Center, Bronx, New York, USA
bDivision of Clinical Microbiology, Mayo Clinic, Rochester, Minnesota, USA
cDivision of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, Minnesota, USA
dTIB MOLBIOL, Adelphia, New Jersey, USA
eDivision of Infectious Diseases, Mayo Clinic, Rochester, Minnesota, USA
The authors declare a conflict of interest. Dr. Patel reports grants from Merck, ContraFect, TenNor Therapeutics Limited and Shionogi. Dr. Patel is a consultant to Curetis, Specific Technologies, Next Gen Diagnostics, PathoQuest, Selux Diagnostics, 1928 Diagnostics, PhAST, and Qvella; monies are paid to Mayo Clinic. Dr. Patel is also a consultant to Netflix. In addition, Dr. Patel has a patent on Bordetella pertussis/parapertussis PCR issued, a patent on a device/method for sonication with royalties paid by Samsung to Mayo Clinic, and a patent on an anti-biofilm substance issued. Dr. Patel receives an editor's stipend from IDSA, and honoraria from the NBME, Up-to-Date and the Infectious Diseases Board Review Course. Scott A. Cunningham reports receiving an honorarium from the Antibiotic Resistance Leadership Group.